http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Oct 2025 02:00:47 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html <p>SpringWorks Therapeutics Inc. announced that long-term efficacy and safety data from its Phase 3 DeFi trial of OGSIVEO (nirogacestat) for adults with desmoid tumors have been published in the Journal of Clinical Oncology. The data utilized a December 2024 cutoff date representing the final analysis of the clinical trial.</p> <p>The updated results showed that objective response rates improved with extended treatment duration. The response rate increased from 34.3% in year one to 45.7% in patients who received OGSIVEO for up to four years. The analysis included three additional complete responses and three additional partial responses since the primary analysis, yielding 24 http://www.streetinsider.com/FDA/SpringWorks+publishes+long-term+data+on+desmoid+tumor+drug+OGSIVEO/25477876.html Tue, 21 Oct 2025 02:00:47 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Press+Releases/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html <p>STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment, were published in the <em>Journal of Clinical Oncology (JCO). </em>The long-term follow-up data from DeFi, which was a global, randomized, multicenter, double-blind, placebo-controlled trial, were previously presented at the 2024 Connective Tissue Oncology Society Meeting. The new results published in <em>JCO</em> utilized a December http://www.streetinsider.com/Globe+Newswire/SpringWorks+Therapeutics+Announces+Publication+of+Long-Term+Efficacy+and+Safety+Data+from+the+Phase+3+DeFi+Trial+of+OGSIVEO%C2%AE+%28nirogacestat%29+in+Adults+with+Desmoid+Tumors+in+the+Journal+of+Clinical+On/25477873.html Tue, 21 Oct 2025 02:00:00 -0400 A.07954646 A.33615634 A.50114125 O.03285413 O.07116439 O.40821812 SWTX http://www.streetinsider.com/Corporate+News/European+Commission+approves+OGSIVEO+for+adults+with+desmoid+tumors/25216849.html <p>The European Commission granted marketing authorization for OGSIVEO (nirogacestat), an oral gamma secretase inhibitor developed by SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany. The drug is approved as monotherapy for treating adults with progressing desmoid tumors who require systemic treatment.</p><p>OGSIVEO represents the first therapy approved in the European Union specifically for desmoid tumors, which are rare, locally aggressive tumors forming in connective tissues. The European Union sees approximately 1,300 to 2,300 new desmoid tumor cases diagnosed annually.</p><p>The approval stems from results of the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors. The http://www.streetinsider.com/Corporate+News/European+Commission+approves+OGSIVEO+for+adults+with+desmoid+tumors/25216849.html Mon, 18 Aug 2025 09:11:48 -0400 SWTX http://www.streetinsider.com/FDA/European+Commission+approves+OGSIVEO+for+adults+with+desmoid+tumors/25216849.html <p>The European Commission granted marketing authorization for OGSIVEO (nirogacestat), an oral gamma secretase inhibitor developed by SpringWorks Therapeutics, a healthcare company of Merck KGaA, Darmstadt, Germany. The drug is approved as monotherapy for treating adults with progressing desmoid tumors who require systemic treatment.</p><p>OGSIVEO represents the first therapy approved in the European Union specifically for desmoid tumors, which are rare, locally aggressive tumors forming in connective tissues. The European Union sees approximately 1,300 to 2,300 new desmoid tumor cases diagnosed annually.</p><p>The approval stems from results of the Phase 3 DeFi trial, which enrolled 142 adult patients with progressing desmoid tumors. The http://www.streetinsider.com/FDA/European+Commission+approves+OGSIVEO+for+adults+with+desmoid+tumors/25216849.html Mon, 18 Aug 2025 09:11:48 -0400 SWTX http://www.streetinsider.com/Press+Releases/European+Commission+Grants+Approval+of+OGSIVEO%C2%AE+%28nirogacestat%29+for+the+Treatment+of+Adults+with+Desmoid+Tumors/25216848.html <p align="left">STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union (EU) to treat desmoid tumors.</p> <p>“Desmoid tumors can have a profound impact on people’s lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, http://www.streetinsider.com/Press+Releases/European+Commission+Grants+Approval+of+OGSIVEO%C2%AE+%28nirogacestat%29+for+the+Treatment+of+Adults+with+Desmoid+Tumors/25216848.html Mon, 18 Aug 2025 09:10:00 -0400 A.50114125 A.60012004 O.01304637 O.40821812 SWTX http://www.streetinsider.com/Press+Releases/European+Commission+Grants+Approval+of+OGSIVEO%C2%AE+%28nirogacestat%29+for+the+Treatment+of+Adults+with+Desmoid+Tumors/25216848.html <p align="left">STAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted marketing authorization for OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor, as monotherapy for the treatment of adults with progressing desmoid tumors who require systemic treatment. OGSIVEO is the first and only therapy approved in the European Union (EU) to treat desmoid tumors.</p> <p>“Desmoid tumors can have a profound impact on people’s lives and are difficult to manage due to their invasive nature and high rates of recurrence. Until now, http://www.streetinsider.com/Press+Releases/European+Commission+Grants+Approval+of+OGSIVEO%C2%AE+%28nirogacestat%29+for+the+Treatment+of+Adults+with+Desmoid+Tumors/25216848.html Mon, 18 Aug 2025 09:10:00 -0400 A.50114125 A.60012004 O.01304637 O.40821812 SWTX